Apexigen Company

Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult to treat diseases. The company’s proprietary technology platform enables the discovery and development of superior antibody product candidates that are able to impact previously inaccessible disease mechanisms.
While many companies are working to develop antibody therapies based on mouse- or human-derived antibody technologies, Apexigen is pioneering a movement into therapeutics based on rabbit-derived humanized monoclonal antibodies as a means of providing therapeutic benefits that have not been achieved through the use of other technologies.
Technology: Pharmaceuticals
Industry: Regenerative medicine
Headquarters: United States
Founded Date: 2010
Employees Number: 11-50
Funding Status: Late Stage Venture
Investors Number: 10
Total Funding: $158M
Estimated Revenue: $1M to $10M
Last Funding Type: Series C

Visit Website
info@apexigen.com
Register and Claim Ownership